CureMatch
×
  • Physicians
    • Patients
  • About Us
  • News
    • CureMatch News
    • Validation and Research
    • Events & Conferences
  • Contact

CureMatch Presents Winning Personalized Medicine & Drug Discovery Abstract at AIMed

CureMatch Presents Winning Personalized Medicine & Drug Discovery Abstract at AIMed
Press

Laguna Niguel, CA – December 13, 2017: Igor F. Tsigelny, Ph.D. and Eden Romm of CureMatch will be presenting at AIMed, the most comprehensive conference on Artificial Intelligence (AI) in medicine, on Wednesday, December 13. Romm and Tsigelny along with Valentina L. Kouznetsova authored “Machine-Learning Models for Selection of Drug-Candidates for Treatment of Alzheimer’s Disease”, one of six winning abstracts out of 138 total submissions.

Eden Romm, a medical student at University of California, Santa Barbara and a CureMatch intern will present the poster during the Data and Intelligence IIB: Best Abstracts session in the main auditorium from 10:45-11:45 AM. Igor F. Tsigelny presents another poster during the Abstract Presentations and Reception from 5:30-7:30 on December 13, as well.

Artificial Intelligence in medicine requires interfacing clinical information with analytics to facilitate a data-to-information continuum and ultimately transform knowledge into actionable intelligence. Precision medicine with its complexity and enormity of data to be analyzed is particularly well suited for the portfolio of AI methodologies such as deep learning as similar patients can be identified and assessed. Precision medicine at its highest level requires a disruptive computational platform for new biomedical knowledge discovery.

In, “Machine-Learning Models for Selection of Drug-Candidates for Treatment of Alzheimer’s Disease”, the authors examined the structural, physical, and chemical characteristics of more than a hundred possible drugs for the treatment of Alzheimer’s disease. A machine-learning model was developed for predicting new inhibitors using these descriptors. The method used to build this model is not specific to molecules useful in the fight against Alzheimer’s Disease. For example, new Cancer drugs can be found using this AI approach.

Tsigelny and Romm are research pioneers in intelligent systems and computing. As applied to oncology, the implications of the molecular basis of cancer drugs is extremely important to physicians making decisions on proper tumor treatment. Personalized medicine developments leads to optimal cancer survival rates.

CureMatch is a digital health company which assists physicians with specific treatment decisions on a patient-by-patient basis. Factoring genomics and proteomics information, millions of potential combinations of cancer drugs in massive clinical and pharmacological knowledge databases are scored. Personalized Combination Therapy™ options are ranked using the actionable intelligence generated by proprietary algorithms scouring evidence-based, custom-curated databases. Improved outcomes are the result of matching treatments at the molecular level.

About AIMed
AIMed is the most comprehensive, multidisciplinary conference on artificial intelligence in medicine. We seek to break new ground in the worlds of decision support & hospital monitoring, medical imaging & biomedical diagnostics, precision medicine & drug discovery, cloud computing & big data, digital medicine & wearable technology, and robotic technology and virtual assistants. Our conference, held December 11-14 at the beautiful Ritz-Carlton Laguna Niguel, brings together the leading minds from the worlds of medicine, data science and more.

Link to Winning Abstract
“Machine-Learning Models for Selection of Drug-Candidates for Treatment of Alzheimer’s Disease” https://ai-med.io/

About CureMatch
CureMatch®, Inc. is a San Diego-based digital health company focused on personalized medicine and combination therapy in oncology. CureMatch’s Decision Support System guides oncologists in the selection of cancer drugs that are customize for individual patients based on their molecular tumor profile. CureMatch enables oncologists to become experts in personalized medicine by providing them with actionable intelligence towards advanced cancer treatment options. www.curematch.com.

Media Contact
Name: Larissa Anderson
Company: CureMatch
Phone: 858-859-2873
Email: press@curematch.com

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • CureMatch Appoints Visionary Leader, Ally Perlina, as Chief Science Officer

    Leader brings two decades of industry experience in precision medicine, pharmaceutical and translational science to...

  • Biomarkers Aren’t Consistently Used to Select Participants for Immunotherapy Trials

    Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for patients with cancer....

  • Servier and CureMatch® Launch Their Self-Certified CE-Marked Clinical Decision Support Software, Bionov™

    PARIS and SAN DIEGO, Oct. 12, 2020 /PRNewswire/ — WeHealth™ Digital Medicine, Servier Group’s e-health business unit, and CureMatch®, a...

  • How Precision Medicine Can Help You

    Precision medicine is revolutionizing cancer care. Dr. Razelle Kurzrock highlights how personalized treatments improve patient...

  • 64 FDA-Approved Drugs Identified as Potential Treatments for COVID-19

    Scientists from CureMatch and UCSD use pharmacophore-based drug design and a molecular docking technique to...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription drugs in the...

Validation

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

  • CureMatch at WIN Symposium 2018 Winning the War against Cancer with Precision Oncology

    SAN DIEGO, CA – June 22, 2018 – CureMatch, Inc. offers results...

  • Personalized Drug Combinations Can Lead to Better Results for Cancer Patients

    A featured article in The Scientist magazine highlights CureMatch co-founder Dr. Razelle...

Archives

  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 859-2873

FAX: +1 (858) 430-5813

Quick Links

  • Physicians
  • About CureMatch
  • News and Latest Posts
    • CureMatch News
    • Validation and Case Studies
    • Events and Conferences
  • Contact Us
  • FAQ

Latest News and Results

  • CureMatch Appoints Visionary Leader, Ally Perlina, as Chief Science Officer Dec 15

    Leader brings two decades of industry experience in precision medicine, pharmaceutical and translational science to...

  • Biomarkers Aren’t Consistently Used to Select Participants for Immunotherapy Trials Dec 13

    Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy Oct 19

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for patients with cancer....

© 2021 CureMatch, Inc. CureMatch is a registered trademark.
FAQ | Terms of Use | Privacy Policy | HIPAA Notice

We’d like to send you a CureMatch Sample Analysis

 

Sample Analysis Download Form

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data